Skip to content

Drug Treatment Availability and Satisfaction Survey

ITP Treatment Availability Survey

Towards the end of 2025 Eltrombopag (one of a class of drugs for ITP known as TPO-RAs) came off patent and a generic version was made available at a greatly reduced cost to the NHS.

At the time it was agreed that 'Patients currently stabilised/established on a different TPO RA should continue with this treatment’.

At the ITP Support Association we have been receiving reports from some patients that they are being advised they will be taken off there current (TPO-RA) treatment and moved to Generic Eltrombopag.

This survey is designed to identify how much of this 'switching' is taking place.

With this survey, no user or identification information is stored The results of this survey will be published on our website and social media channels.
1.Which TPO-RA drug are you currently being prescribed?
2.How satisfied are you with the effectiveness of your current TPO-RA medication?
3.Has your NHS Trust indicated a switch to the Generic Eltrombopag?
4.How do you feel about the potential switch to Generic Eltrombopag?
5.What concerns, if any, do you have about switching to Generic Eltrombopag? Select all that apply.
6.Have you discussed the potential switch with your healthcare provider?
7.How confident are you in your healthcare provider's decision regarding your medication?
8.Which NHS Trust and Hospital are you being treated at?
9.Please provide any additional comments or concerns about your TPO-RA treatment.